Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | CHKA | P35790 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.53 |
| ▸ | CCR3 | P51677 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL266138 | 0.89 | NPC1 (0.71) | RAB9ANPC1ACHEALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL28652893 | 0.87 | NPC1 (0.69) | RAB9ANPC1ACHEALDH1A1MEN1 | |
| Methane SCHEMBL28444324 | 0.87 | NPC1 (0.69) | RAB9ANPC1ACHEALDH1A1MEN1 | |
| Ethane SCHEMBL27302230 | 0.86 | ACHE (0.68) | RAB9ANPC1CYP2D6ACHEALDH1A1 | |
| SCHEMBL27569958 | 0.85 | HRH3 (0.57) | RAB9ANPC1KCNH2HRH3CYP2D6 | |
| SCHEMBL4772746 | 0.85 | HRH3 (0.57) | RAB9ANPC1KCNH2HRH3CYP2D6 | |
| SCHEMBL24093051 | 0.83 | HRH3 (0.86) | KCNH2HRH3CYP2D6CYP2C19ACHE | |
| SCHEMBL22432783 | 0.83 | ALDH1A1 (0.76) | RAB9ANPC1HRH3CYP2D6CYP2C19 | |
| SCHEMBL5401732 | 0.83 | ALDH1A1 (0.76) | RAB9ANPC1HRH3CYP2D6CYP2C19 | |
| SCHEMBL2272254 | 0.82 | FUCA1 (0.58) | KCNH2HRH3CYP2D6CYP2C19CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116351103-A | Chromatography medium and preparation method and application thereof | 百林科(兰州)新材料有限公司 | 2023-06-30 | — | — | CN | claimed |
| CN-116351103-A | Chromatography medium and preparation method and application thereof | 百林科(兰州)新材料有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20210353642-A1 | COMPOUNDS FOR TREATING MYELIN RELATED DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2021-11-18 | — | — | US | disclosed |
| WO-2021224864-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353642-A1 | COMPOUNDS FOR TREATING MYELIN RELATED DISORDERS | PMP22, MAG, MYT1 | RAB9A 1622/4885NPC1 60/4885KCNH2 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.